Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event
December 02 2020 - 7:30AM
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience
company, today announced that Meghna Malik, Ph.D., Senior Director,
will present at the 4th CRISPR AgBio Congress which is being held
December 1-3, 2020 as a virtual event.
Dr. Malik’s presentation is titled “Yield10 trait development:
Using CRISPR to increase seed yield and oil content in Camelina.”
The presentation will be part of the “Expanding the CRISPR scope to
more challenging agricultural crops” session which is scheduled at
6:00 pm EST on Dec. 2. Dr. Malik will also participate in a Virtual
Roundtable titled “Analyzing the next generation of promising
target traits: Revolutionizing the future of agriculture,” which is
scheduled at 3:00 pm EST on Dec. 3.
In her presentation, Dr. Malik will discuss the approach taken
by Yield10 and its wholly owned subsidiary, Metabolix Oilseeds, to
deploy novel traits in the oilseed crops Camelina sativa and canola
using CRISPR genome-editing to increase seed yield and oil content.
The presentation describes the simultaneous editing of three gene
targets (C3008a, C3008b, C3009) designed to reduce the oil turnover
during seed maturation. To do this, the researchers simultaneously
edited nine genes in Camelina using CRISPR. Different combinations
of edits were obtained and characterized. Dr. Malik will present
data obtained from a triple edited Line E3902 showing a five
percent increase in total oil produced per plant in greenhouse
studies and a calculated 15 percent increase in total oil produced
per hectare in field tests conducted in 2019.
Dr. Malik will also highlight Yield10’s work with the novel oil
content trait C3007, which disrupts BADC, a novel negative
regulator of acetyl-CoA carboxylase (ACCase), a key enzyme in fatty
acid biosynthesis. Yield10 has obtained stable edits for select
badc genes and gene combinations deployed in Camelina and canola.
In greenhouse studies, certain combinations of CRISPR-edited BADC
targets deployed in Camelina have shown an increase in oil produced
per plant. In 2020, Yield10 conducted its first field trials of
BADC (C3007) edited Camelina lines in the U.S. Yield10 has also
produced C3007 canola lines where an increase in oil produced per
plant has been observed in greenhouse studies.
“Our presentation highlights our success deploying multiple
CRISPR edits in a complex genome crop like Camelina and translating
the greenhouse research to field testing to obtain the positive
outcome of increasing oil content,” said Meghna Malik, Ph.D.,
Senior Director of Metabolix Oilseeds, the Canadian subsidiary of
Yield10 Bioscience. “Our research with these CRISPR-edited Camelina
and canola lines is intended to increase seed oil content to
maximize oil yields per acre. We also see the potential to combine
or stack these CRISPR edits with oil composition traits, such as
Camelina omega-3 (DHA+EPA), to increase yield and hence the
economic value of engineered crops. We look forward to reporting
further results for these traits as our work continues to progress
in 2021.”
Yield10 recently announced a collaboration with Rothamsted
Research to develop advanced technology for producing omega-3
(DHA+EPA) nutritional oils in Camelina.
Learn more about the conference at the 4th CRISPR AgBio Congress
website. A copy of Dr. Malik’s slide deck is available on the
Yield10 Bioscience website.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
developing crop innovations for sustainable global food security.
The Company uses its “Trait Factory” including the “GRAIN” big data
mining trait gene discovery tool as well as the Camelina oilseed
“Fast Field Testing” system to develop high value seed traits for
the agriculture and food industries. As a path toward
commercialization of novel traits, Yield10 is pursuing a partnering
approach with major agricultural companies to drive new traits into
development for canola, soybean, corn, and other commercial crops.
The Company is also developing improved Camelina varieties as a
platform crop for the production and commercialization of
nutritional oils, proteins, and PHA biomaterials. The Company’s
expertise in oilseed crops also extends into canola, where it is
currently field-testing novel yield traits to generate data to
drive additional licensing opportunities. Yield10 is headquartered
in Woburn, MA and has an Oilseeds Center of Excellence in
Saskatoon, Canada.
For more information about the company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn.
(YTEN-G)
Safe Harbor for
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, the use of the Company’s technology to successfully
identify targets and develop systems using CRISPR genome editing
for increasing crop yield and oil content, the timing for reporting
of further results, the ability of greenhouse studies to predict
yield results in field tests, and progress by Yield10 in driving
increases in oil biosynthesis and developing its products,
constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated, including the risks and uncertainties detailed in
Yield10 Bioscience's filings with the Securities and Exchange
Commission. Yield10 assumes no obligation to update any
forward-looking information contained in this press release or with
respect to the matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From May 2023 to May 2024